The global influenza vaccines market size is slated to reach USD 7.34 billion by 2026, exhibiting a CAGR of 7.7% during the forecast period. Increasing prevalence of influenza worldwide will be the major driving force behind the growth of this market. According to the World Health Organization (WHO), around 3 to 5 million cases of influenza-based diseases are reported annually across the globe. This has spurred governments to take proactive measures to contain the spread of this deadly disease. Many governments carry out extensive vaccination drives before the flu season begins to immunize people from contracting any such infections, bolstering the seasonal influenza vaccines market demand. At the global level, organizations such as the WHO and the United Nations’ Children Fund (UNICEF) regularly recommend various seasonal and general influenza vaccines to regional public authorities. These factors are expected to give rise to a robust growth period for this market.
Request a Sample Copy of the Global Influenza Vaccine Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/influenza-vaccine-market-101896
Top Players Profiled:
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc.
- Sinovac Biotech Ltd
- CSL Limited
- Emergent BioSolutions Inc.
- Live Attenuated
By Age Group
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Presence of a Few Players to Make Competition Tight
Through its influenza vaccines market report, Fortune Business Insights™ has brought out an in-depth analysis of the competition in this market. The report states that the competitive landscape will be dotted by a few key players who are increasing their investment in enhancing their R&D capacities to widen their product portfolio.
Key Industry Developments:
- November 2019: Sanofi received clearance for its Fluzone®High-Dose Quadrivalent from the US Food and Drug Administration (FDA). Containing an additional Influenza B strain, the drug is designed and aimed at treating adults at and over the age of 65.
- January 2019: The European Commission green lit Seqirus’s FLUCELVAX® TETRA for marketing in Europe. This is a cell-based quadrivalent influenza vaccine, the first of its kind to be marketed in Europe, which is to be used on people aged 9 years and above.
More Trending Topics From Fortune Business [email protected]